Overview
Oncology healthcare professionals who treat patients with lung cancer have an increasing array of diagnostic and therapeutic tools at their disposal. These include the use of immunotherapy and targeted therapy in early-stage and locally advanced disease, as well as in metastatic lung cancer. Additionally, new classes of agents have become available, such as bispecific antibodies and antibody-drug conjugates. These developments have the potential to improve outcomes for patients with lung cancer but also bring new considerations for implementation, including adequate testing and adverse event management.
The 26th Annual International Lung Cancer Congress® will distill the latest data on targeted agents, immunotherapy, surgery, and radiation oncology for the management of lung cancer. This event will also include a special visionary session with the annual Addario Keynote Lecture and an expert panel discussion on coming trends in lung cancer therapy over the next decade. As in previous years, cutting-edge lectures, multidisciplinary case-based tumor boards, and question-and-answer sessions will allow participants to engage with international and national experts as they share their perspectives and personal experiences of clinical challenges and ongoing controversies in lung cancer management.
Related Files